Comparison of antifungal MICs for yeasts obtained using the EU-CAST method in a reference laboratory and the Etest in nine different hospital laboratories  by Dannaoui, E. et al.
Comparison of antifungal MICs for yeasts obtained using the EUCAST
method in a reference laboratory and the Etest in nine different
hospital laboratories
E. Dannaoui1, A. Paugam2, M. Develoux3, C. Chochillon4, J. Matheron5, A. Datry6, C. Bouges-Michel7, C. Bonnal8, F. Dromer9
and S. Bretagne10
1) Universite´ Paris Descartes, Faculte´ de Me´decine, AP-HP, Hoˆpital Europe´en Georges Pompidou, Unite´ de Parasitologie–Mycologie, 2) Universite´ Paris
Descartes, Faculte´ de Me´decine, AP-HP, Hoˆpital Cochin, Laboratoire de Parasitologie-Mycologie, 3) AP-HP, Hoˆpital Saint-Antoine, Laboratoire de Parasitolo-
gie-Mycologie, 4) AP-HP, Hoˆpital Bichat, Laboratoire de Parasitologie-Mycologie, 5) Universite´ Paris Descartes, Faculte´ de Me´decine, AP-HP, Hoˆpital Necker-
Enfants-Malades, Unite´ de Parasitologie-Mycologie, 6) AP-HP, Hoˆpital Pitie´ Salpe´trie`re, Laboratoire de Parasitologie-Mycologie, Paris, 7) AP-HP, Hoˆpital
Avicenne, Laboratoire de Parasitologie-Mycologie, Bobigny, 8) AP-HP, Hoˆpital Biceˆtre, Laboratoire de Parasitologie-Mycologie, Le Kremlin-Biceˆtre, 9) Institut
Pasteur, Centre National de Re´fe´rence des Mycoses et Antifongiques, Unite´ de Mycologie Mole´culaire, CNRS URA3012, Paris and 10) Universite´ Paris-EST,
Faculte´ de me´decine, AP-HP, Hoˆpital Henri-Mondor, Laboratoire de Parasitologie-Mycologie, Cre´teil, France
Abstract
In routine laboratory practice, the determination of MICs of antifungals for yeasts often relies on the Etest, because of a good correla-
tion with reference methods. However, this correlation was established through predesigned studies, rather than prospective testing.
The surveillance programme of fungaemia (YEASTS programme), implemented since 2003, facilitated our comparison of the Etest and
the EUCAST results, obtained on a routine basis in nine different hospitals and in a reference laboratory, respectively. The analysis
included 690 isolates recovered from blood culture (362 Candida albicans, 113 Candida glabrata, 69 Candida parapsilosis, 55 Candida tropi-
calis, 31 Cryptococcus neoformans, and 60 other yeast species) that were tested for their susceptibility to amphotericin B (n = 655), ﬂuco-
nazole (n = 669), itraconazole (n = 198), voriconazole (n = 588), ﬂucytosine (n = 314), and caspofungin (n = 244). Agreement between
the Etest and EUCAST datasets was calculated and categorized on the basis of previously published breakpoints. The level of agreement
at ±2 dilutions was 75% for amphotericin B and 90% for ﬂucytosine; for the azoles, it ranged from 71% for itraconazole to 87% for
voriconazole. No signiﬁcant difference was observed among the yeast species, except for Cryptococcus neoformans and ﬂucytosine, with
an agreement <40%. Categorical agreement ranged from 60% for itraconazole to 90% for ﬂucytosine. Major and very major discrepan-
cies occurred in <12% and 6%, respectively. The Etest, even when performed on a routine basis, shows a ‡71% agreement with the
EUCAST reference method.
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Introduction
Candidaemia is still associated with a poor prognosis,
showing a mortality rate of 30–40% [1]. This can be
explained by predisposing conditions in the patients [2].
Poor prognosis could also be due, at least in part, to the
isolate itself and to its susceptibility to antifungals [3,4].
The availability of several effective antifungals with good
safety proﬁles and different spectra has raised the issue of
the clinical relevance of MIC data. Only standardized pro-
cedures are of use to clinicians and epidemiologists [5,6].
The CLSI has developed a broth reference procedure [7].
The Antifungal Susceptibility Testing Subcommittee of the
European Committee on Antibiotic Susceptibility Testing
(AFST-EUCAST) has also developed a reference method
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for fermentative yeasts [8]. The results of CLSI and EU-
CAST microdilution procedures show an overall agreement
of ‡92% for the main antifungal agents [9,10].
However, these reference procedures are difﬁcult to imple-
ment in a routine clinical laboratory, as their design complexity
is not suited to use on a case-per-case basis. Other systems
are easier to use, are commercially available, provide rapid
results, and compare favourably with the reference tests
[11,12]. Among them, the Etest, an agar diffusion method,
which uses a strip of inert material impregnated with a prede-
ﬁned concentration gradient of antifungal to determine an MIC
value, is widely used in routine laboratories.
Correlations between reference methods and Etest results
have usually been established in a given reference laboratory
[11,13–16], or during speciﬁcally designed time-limited stud-
ies [12,17]. These studies established the rationale for Etest
use, but did not reﬂect the situations prevalent during actual
routine use and could have overestimated the correlation,
overlooking the difﬁculties in interpreting and adhering to
the protocol in clinical and laboratory settings.
The French National Reference Centre for Mycoses and
Antifungals (NRCMA, Institut Pasteur, Paris) has implemented
an active surveillance programme of yeast fungaemia (YEASTS
programme) in hospitals within the Paris area. We took
advantage of this programme to compare results obtained
with the two methods, Etest and EUCAST. In the participating
laboratory, it was part of the routine procedure for isolates
responsible for deep-seated infections to be tested using the
Etest; at the NRCMA, all isolates are systematically tested by
the EUCAST method (modiﬁed for amphotericin B and caspo-
fungin by using AM3 medium in place of RPMI). The speciﬁc
aim of the present study was to assess whether the good
correlation between the Etest and broth dilution methods
could be extended to routine use in hospital laboratories.
Materials and Methods
Yeast isolates and data collection
All yeasts recovered from blood culture in the participating
laboratories and sent to the NRCMA as part of the YEASTS
programme, from 2003 to 2006, were prospectively analysed
for their susceptibility in vitro to systemic antifungals. Identiﬁca-
tion was conﬁrmed using ID32C strips (BioMe´rieux, Marcy
l’Etoile, France) and ITS1–5.8S–ITS2 sequencing for species
other than Candida albicans, Candida glabrata, Candida tropicalis,
Candida parapsilosis, and Cryptococcus neoformans. Species-spe-
ciﬁc PCR reactions were performed to differentiate Candida
dubliniensis from C. albicans [18]. The 690 isolates from blood
cultures included in the study comprised 362 C. albicans, 113
C. glabrata, 69 C. parapsilosis, 55 C. tropicalis, 31 Cryptococcus
neoformans, and 60 other yeast species (14 Candida guilliermon-
dii, 11 Candida krusei, 11 Candida kefyr, six C. dubliniensis, six
Candida lusitaniae, two Saccharomyces cerevisiae, and one each
of Candida fermentati, Candida haemulonii, Candida pelliculosa,
Candida rugosa, Candida sphaerica, Candida utilis, Pichia ohmeri,
Rhodotorula mucilaginosa, Rhodotorula sp., and Trichosporon loubi-
eri). Pure samples of the following antifungals were used,
obtained in powder form and of known potency: amphoteri-
cin B (Sigma-Aldrich, St Quentin Fallavier, France), ﬂuconazole
(Pﬁzer, Sandwich, UK), itraconazole (Janssen-Cilag, Issy-les-
Moulineux, France), voriconazole (Pﬁzer), ﬂucytosine (Sigma-
Aldrich), and caspofungin after December 2004 (Merck,
Rahway, NJ, USA). In vitro susceptibility was determined by
following the guidelines in the AFST-EUCAST deﬁnitive docu-
ment 7.1 [8] or a modiﬁed EUCAST technique, using AM3
medium in place of RPMI for amphotericin B and caspofungin.
Microplates were prepared in batches and stored frozen at
)20C for <2 months. Two reference strains, C. krusei
ATCC 6258 and C. parapsilosis ATCC 22019, were included in
each sample set, to ensure quality control.
No speciﬁc guidelines for performing Etests were given to
the hospital laboratories, as collecting the Etest data was not
part of the YEASTS programme. Determination of the MIC
using the Etest followed local practices and was performed
prospectively, independently of the determination by the EU-
CAST method at the NRCMA. All laboratories used RPMI agar
with 2% glucose, and MICs were determined when growth
was clearly seen after 24–48 h, as recommended by the manu-
facturer (AB Biodisk, Solna, Sweden). Some hospitals did not
test all of the available Etest antifungal strips on each isolate.
However, missing values were not obtained retrospectively.
Data analyses
Low off-scale values were left unchanged, and high off-scale
values were converted to the next higher concentration. For
calculations, the Etest MICs were raised to the next corre-
sponding EUCAST concentration. Agreement was deﬁned as
differences of no more than two dilutions between results
obtained by the two techniques.
Categorical agreement was deﬁned as the percentage of
isolates classiﬁed into the same category with both methods,
based on breakpoints previously published for all antifungals
except caspofungin [11,19,20]. Tentative interpretative
breakpoints were those recommended by EUCAST for
ﬂuconazole [19] (susceptible £2 mg/L, intermediate 4 mg/L,
and resistant ‡8 mg/L) and for voriconazole [20] (susceptible
£0.125 mg/L, and resistant ‡0.25 mg/L), and those used pre-
viously [11] for amphotericin B (susceptible £0.25 mg/L,
intermediate 0.50–1.0 mg/L, and resistant ‡2 mg/L), ﬂucyto-
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sine (susceptible £4 mg/L, intermediate 8–16 mg/L, and resis-
tant ‡32 mg/L), and itraconazole (susceptible £0.12 mg/L,
intermediate 0.25–0.50 mg/L, and resistant ‡1 mg/L). For
caspofungin, on the basis of MIC determinations for wild-
type and fks1 mutant isolates [21], the following breakpoints
were used: susceptible £0.25 mg/L, and resistant ‡0.5 mg/L
[22]. Discrepancies were considered to be very major if an
isolate classiﬁed as resistant by the reference method was
categorized as susceptible by the commercial method. Dis-
crepancies were considered to be major if an isolate classi-
ﬁed as susceptible by the reference method was classiﬁed as
resistant by the commercial technique. Errors were classiﬁed
as minor when susceptible vs. intermediate, resistant vs.
intermediate, intermediate vs. susceptible or intermediate
vs. resistant discrepancies were observed [12].
Statistical tests
Distributions of MICs were compared with a Mann–Whitney
test. The percentage of species and the percentage of agree-
ment were compared using the chi-square test. Correlation
between the percentage of agreement and the number of
isolates tested was calculated using a Spearman test. Statisti-
cal signiﬁcance was deﬁned as p £0.05.
Results
Nine hospitals of the YEASTS programme participated in the
study and provided their data. The mean number of isolates
in each centre was 77 (range 39–130).
The nine laboratories were not statistically different with
regard to the species distribution (p 0.08). With the use of
the EUCAST method, or the modiﬁed EUCAST method for
amphotericin B and caspofungin, broad MIC ranges of each
antifungal agent were observed. Overall, the resistant isolates
ranged from 0.3% for amphotericin B to 21.5% for ﬂuconaz-
ole. MICs for C. krusei ATCC 6258 and C. parapsilosis
ATCC 22019 were within the expected range [23].
Table 1 shows the overall agreement in MIC values,
grouped according to the centre. The agreement at ±2 dilu-
tions ranged from 70.7% (itraconazole) to 90.4% (ﬂucyto-
sine). The number of drugs tested per isolate differed:
amphotericin B, ﬂuconazole and voriconazole were tested
more than 580 times; itraconazole and ﬂucytosine Etest
strips were not used in two centres, and were tested 198
and 314 times, respectively, in the other centres; and caspo-
fungin Etest strips were not available before 2005 (244
tests). The agreement was signiﬁcantly lower for two labora-
tories (H and I; p <0.001 and p <0.05, respectively), and bet-
ter for two others (E and F; p <0.05). The differences relied
only on amphotericin B (p <0.001), ﬂuconazole, and ﬂucyto-
sine (p <0.01). The percentage of agreement was not corre-
lated with the number of tests performed per laboratory
(Spearman r = 0.503, p 0.14). Fig. 1 shows the overall com-
parisons between the Etest and EUCAST MIC values. Etest
median MICs were two-fold to four-fold higher (p <0.0001)
than the MICs obtained by the EUCAST method (or the
modiﬁed EUCAST method for amphotericin B and caspofun-
gin) for all the antifungals tested except ﬂucytosine. For
C. albicans, C. glabrata, C. tropicalis and C. parapsilosis, this was
always true for amphotericin B and caspofungin (p <0.0001).
For the azoles, Etest MICs were also always higher than EU-
CAST MICs for C. albicans (p <0.0001). For C. glabrata, C. par-
apsilosis, and C. tropicalis, Etest MICs of azoles were also
always higher than EUCAST MICs, even though differences
were not always signiﬁcant.
Table 2 presents the agreement at ±2 dilutions observed
according to species. No particular species, or any given anti-
TABLE 1. Agreement between the Etest MICs and EUCAST MICs according to the participating centres
Centre
Percentage agreement (±2 log2 dilutions) for
AMB FCZ ITZ VRZ 5FC CAS
n Agreement (%) n Agreement (%) n Agreement (%) n Agreement (%) n Agreement (%) n Agreement (%)
A 54 72.2 57 63.2 1 100.0 46 84.8 51 92.2 18 100.0
B 23 82.6 46 54.3 2 100.0 46 80.4 26 96.2 16 81.3
C 39 84.6 39 53.8 ND ND 2 100.0 ND ND ND ND
D 100 86.0 97 77.3 49 75.5 101 87.1 ND ND 50 80.0
E 95 84.2 93 79.6 28 71.4 78 85.9 79 87.3 25 68.0
F 107 79.4 107 79.4 107 67.3 107 91.6 106 97.2 26 61.5
G 52 75.0 48 70.8 7 71.4 40 90.0 38 81.6 29 82.8
H 129 58.1 129 71.3 ND ND 128 85.9 1 0.0 48 66.7
I 56 62.5 53 71.7 4 75.0 40 80.0 13 69.2 32 71.9
All centres 655 75.0 669 71.7 198 70.7 588 86.6 314 90.4 244 75.0
AMB, amphotericin B; FCZ, ﬂuconazole; ITZ, itraconazole; VRZ, voriconazole; 5FC, ﬂucytosine; CAS, caspofungin; ND, not done.
For amphotericin B and caspofungin, a modiﬁed EUCAST technique was adopted, using AM3 medium.
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FIG. 1. Comparison of MIC distribution of amphotericin B (AM), ﬂuconazole (FCZ), itraconazole (ITZ), voriconazole (VRZ), ﬂucytosine (5F),
and caspofungin (CA) determined by Etest (white bars) and EUCAST (black bars) methods. For amphotericin B and caspofungin, a modiﬁed EU-
CAST technique was adopted, using AM3 medium.
TABLE 2. Agreement (±2 dilutions) between the Etest MICs and EUCAST MICs according to the species
Yeast species Total (n = 690) AMB% (n = 655) FCZ% (n = 669) ITZ% (n = 198) VRZ% (n = 588) 5FC% (n = 314) CAS% (n = 244)
Candida albicans 362 80.9 (345) 66.9 (354) 72.5 (109) 88.3 (308) 95.8 (166) 80.0 (120)
Candida glabrata 113 69.2 (104) 72.7 (110) 67.7 (31) 81.6 (98) 100.0 (46) 66.7 (45)
Candida parapsilosis 69 64.7 (68) 78.3 (69) 92.3 (13) 86.4 (59) 92.3 (26) 89.7 (29)
Candida tropicalis 55 61.1 (54) 85.2 (54) 50.0 (14) 81.3 (48) 100.0 (25) 60.0 (20)
Cryptococcus neoformans 31 73.1 (26) 76.7 (30) 72.7 (11) 86.4 (22) 35.0 (20) 100.0 (4)
Other species 60 75.9 (58) 76.9 (52) 65.0 (20) 90.6 (53) 74.2 (31) 57.7 (26)
AMB, amphotericin B; FCZ, ﬂuconazole; ITZ, itraconazole; VRZ, voriconazole; 5FC, ﬂucytosine; CAS, caspofungin; n, number of test performed.
For amphotericin B and caspofungin, a modiﬁed EUCAST technique was adopted, in which AM3 medium was used.
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fungal, was superior than the others, with the exception of
Cryptococcus neoformans in its susceptibility to ﬂucytosine, for
which the agreement was <40%.
Table 3 reports the agreement categorized according to
the chosen tentative breakpoints [11,19,20,22]. This agree-
ment ranged from 59.6% for itraconazole to 90.4% for ﬂucy-
tosine. Minor errors ranged from 5.4% (ﬂucytosine) to 31.3%
(itraconazole). Major discrepancies ranged from 1.2%
(amphotericin B) to 11.9% (caspofungin). Very major discrep-
ancies were observed once (0.02%) for amphotericin B for
one C. albicans isolate, 18 times (2.7%) for ﬂuconazole (nine
C. glabrata, seven C. guilliermondii, and two C. tropicalis), 35
times (5.9%) for voriconazole (one C. albicans, 21 C. glabrata,
two C. guilliermondii, one C. haemulonii, one C. krusei, seven
C. tropicalis, one C. parapsilosis, and one Cryptococcus neofor-
mans), and once (0.4%) for caspofungin (one C. albicans).
Among the 45 isolates that gave very major errors with
azoles, nine isolates (20%) gave these very major errors with
both ﬂuconazole and voriconazole. Very major errors were
observed in all nine participating hospitals.
Discussion
The primary goal of the present study was to verify the
agreement between the Etest and EUCAST methods, per-
formed independently, for in vitro antifungal susceptibility
testing. Instead of designing a study where the results of two
methods are compared within the same laboratory, we
chose to compare results obtained in a reference laboratory
using EUCAST techniques with results obtained on a routine
basis in nine hospital laboratories, using the Etest. Etest data
were those provided by each laboratory to the clinician in
charge of the patients. The overall agreement between Etest
MICs and EUCAST results was ‡71%. As compared with
data obtained in a reference laboratory from 93 isolates
[11], the Etest performed similarly in the present study for
ﬂucytosine (90% vs. 88.9%), but agreement was slightly lower
for the other antifungals (75% vs. 83%, 71% vs. 80%, 72 vs.
95% and 87% vs. 93% for amphotericin B, itraconazole, ﬂuco-
nazole, and voriconazole respectively). Results comparable to
ours were obtained by others testing voriconazole, with an
agreement of 90% between the Etest and EUCAST methods
[9].
The fact that studies with different designs generate similar
results suggests that the technique is robust. Indeed, many dis-
crepancies could have been expected. Although all isolates
were recovered from blood, the species were more varied
than in many studies. The experience of the technicians read-
ing the Etest could differ between laboratories, and the pro-
tracted study length of >3 years may have involved different
technicians over time, with a possible drift in the readings.
Although the Etest is easy to perform, the isolate/species–anti-
fungal combination may affect the zone edge at the MIC inter-
section, with a trailing effect being seen with some isolates
(about 20% of yeasts), and particularly with the azoles. Despite
these issues, the present study even shows that the Etest iden-
tiﬁed most of the in vitro resistant isolates and that Etest
results were comparable to those achieved by EUCAST proce-
dures. Nevertheless, we observed differences in percentage of
agreement among hospitals, and this may lead to interest in
regular quality controls, using the EUCAST method as a refer-
ence. This might be particularly useful for the three antifungals
used to treat candidaemia (i.e. amphotericin B, ﬂuconazole,
and caspofungin), for which agreement between the Etest and
EUCAST methods was <80%.
Categorical agreement is more clinically relevant than
global agreement, as these results can lead to treatment
modiﬁcations [24]. This requires the deﬁnition of interpre-
tive breakpoints, which have yet to be established for most
antifungals, and more speciﬁcally, for new ones such as
caspofungin [5,6]. In this study, the azole with the most
minor and major errors was itraconazole (31.3% and 9.1%,
respectively), as previously reported [11]. This is probably
TABLE 3. Categorical agreement between the Etest and the EUCAST results
AMB FCZ ITZ VRZ 5FC CAS
Categorical agreement n (%) n (%) n (%) n (%) n (%) n (%)
Agreement 507 (77.4) 525 (78.5) 118 (59.6) 509 (86.6) 284 (90.4) 214 (87.7)
Minor 139 (21.2) 89 (13.3) 62 (31.3) NA 17 (5.4) NA
Major 8 (1.2) 37 (5.5) 18 (9.1) 44 (7.5) 13 (4.1) 29 (11.9)
Very major 1 (0.2) 18 (2.7) 0 35 (5.9) 0 1 (0.4)
Total (n) 655 669 198 588 314 244
AMB, amphotericin B; FCZ, ﬂuconazole; ITZ, itraconazole; VRZ, voriconazole; 5FC, ﬂucytosine; CAS, caspofungin; NA, not applicable.
For amphotericin B and caspofungin, a modiﬁed EUCAST technique was adopted, using AM3 medium. The tentative interpretative breakpoints used were those recom-
mended by EUCAST for ﬂuconazole [19] and for voriconazole [20], and those previously used by Cuenca-Estrella et al. [11] for amphotericin B, ﬂucytosine, and itraconazole.
For caspofungin, tentative breakpoints were deﬁned on the basis of MIC determinations for wild-type and fks1 mutant Candida spp. isolates [21].
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not an issue, as itraconazole is not approved or used for
yeast fungaemia. Very major discrepancies were observed
only once (0.2%), with amphotericin B, probably owing to
the small number of true amphotericin B-resistant isolates,
which are usually more easily revealed by the Etest than by
broth microdilution techniques [25,26]. For azoles, the very
major errors were observed for ﬂuconazole and voriconaz-
ole, and mainly for a few species, i.e. C. glabrata, C. guilliermon-
dii and C. tropicalis in the present study, as previously
reported for ﬂuconazole against C. tropicalis [15]. It is of note
that nine of the 45 isolates gave very major errors with both
azoles, suggesting that these discrepancies are related to the
isolates themselves and not to a technical problem. These
very major errors might derive from the trailing growth
observed with the Etest [27]. The trailing growth could
generate higher MIC values than the EUCAST method, as
shown in Fig. 1, explaining minor and major discrepancies,
but not very major ones. Irrespective of the explanations,
major and very major discrepancies occurred in <12% and
6%, respectively.
The present study conﬁrms that the Etest incorrectly gave
high ﬂucytosine MICs for Cryptococcus neoformans, as previ-
ously reported by some groups [27,28], although others have
reported different ﬁndings [29]. This should prompt the use
of other agar media for testing ﬂucytosine on this species
[28]. For caspofungin, data obtained by the Etest are mainly
limited to case reports [25,30]. Recently, by using a well-char-
acterized collection of Candida spp. that were susceptible and
resistant to caspofungin, we showed that the Etest was a valu-
able technique for caspofungin resistance detection [22]. In
the present study, the agreement between the Etest and
results obtained by the modiﬁed EUCAST technique for ca-
spofungin was 75%, which is below the 94% reported in a sin-
gle-centre study [9]. However, the Etest strips for caspofungin
were not available throughout the 3-year study, limiting the
tests performed in each centre, where more experience may
be necessary before data are reproducible. Finally, the use of
AM3 in this study instead of RPMI, as currently recommended
in the EUCAST method, may have increased these discrepan-
cies, as MICs obtained when AM3 broth is used are lower
than those obtained using RPMI broth.
In conclusion, susceptibility testing results obtained by the
Etest method, even if generated in non-reference laborato-
ries, show a >71% correlation with results obtained by the
EUCAST reference method. If the Etest appears to be a suit-
able alternative to the EUCAST method for antifungal sus-
ceptibility testing of clinical isolates of yeasts in routine
practice, the present levels of agreement should be improved
with quality controls. Regular comparisons between central-
ized determination of MICs in a reference laboratory and
the routine results obtained using commercially available
methods could be more representative than the current
practice of performing quality control with a speciﬁc set of a
limited number of isolates.
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